文献速递呼吸道感染呼吸危重症与机械通气

临床宏基因组学对免疫抑制成人肺炎诊断的附加价值

Added Diagnostic Utility of Clinical Metagenomics for the Diagnosis of Pneumonia in Immunocompromised Adults.
PubMed 文献 · Chest · 2020-11-18

本研究前瞻性纳入30例接受支气管镜肺泡灌洗的免疫抑制成人肺炎患者(31次发作),比较常规微生物检测(CMT)与CMT联合临床宏基因组学(CM)的诊断率。CMT联合CM将最终微生物诊断率从35%提高至58%,主要归因于细菌性肺炎的额外检出,但对真菌性肺炎帮助有限。

要点

  • CMT联合CM使免疫抑制成人肺炎微生物诊断率从35%升至58%。
  • 细菌性肺炎诊断率从16%升至42%,真菌性从19%升至23%。
  • CM对真菌性肺炎的附加诊断价值较小。

核心结论

  • CMT联合CM将免疫抑制成人肺炎的诊断率从35%提高至58%,主要归因于额外检出细菌性病因,对真菌性肺炎帮助较小。

研究设计与样本

  • 非干预性前瞻性研究,纳入30例免疫抑制成人肺炎患者(31次肺炎发作),均接受支气管镜和肺泡灌洗,为期2年。
  • 常规微生物检测按标准诊疗进行,商业CM检测在残余肺泡灌洗液上进行。

主要发现

  • 最终微生物诊断:CMT组11例(35%),CMT+CM组18例(58%)。
  • 细菌性肺炎:CMT诊断5例(16%),CMT+CM诊断13例(42%)。
  • 真菌性肺炎:CMT诊断6例(19%),CMT+CM诊断7例(23%)。
  • 病毒性肺炎:CMT诊断2例(6%),CMT+CM诊断5例(16%)。
  • 最终临床诊断:基于CMT为20/31例(65%),基于CMT+CM为23/31例(74%)。

关键数值与推荐

  • CMT+CM对管理的影响:可能1例,或许8例,不太可能2例。
  • CMT+CM对抗菌药物管理的影响:可能13例,不太可能7例。

临床怎么用

  • 在免疫抑制成人肺炎中,常规微生物检测基础上加做CM可提高微生物诊断率,尤其针对细菌性病因。
  • CM对真菌性肺炎的附加诊断价值有限,临床解读需结合常规检测结果。

局限性

  • 样本量小(30例患者,31次发作),为非干预性研究。
  • 对管理和抗菌药物管理的影响为假设性评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the evaluation of community-acquired pneumonia, 30% to 60% of cases remain undiagnosed, despite extensive conventional microbiologic testing (CMT). Clinical metagenomics (CM) is an unbiased pathogen detection method that can increase diagnostic yield. RESEARCH QUESTION: Does adding clinical metagenomics to conventional microbiologic testing improve the diagnostic yield for pneumonia in immunocompromised adults? STUDY DESIGN AND METHODS: We performed a noninterventional prospective study of immunocompromised adults with pneumonia who underwent bronchoscopy and BAL over 2 years. CMT was performed per standard of care. A commercial CM test was performed on residual BAL fluid. Final microbiologic diagnoses were based on CMT vs CMT + CM. Final clinical diagnoses for CMT and CMT + CM were made based on laboratory results in conjunction with clinical and radiologic findings. Hypothetical impact of CMT + CM on management and antimicrobial stewardship was also assessed. RESULTS: A total of 30 immunocompromised adult patients (31 episodes of pneumonia) were included. Final microbiologic diagnoses were made in 11 cases (35%) with the use of CMT and in 18 cases (58%) with the use of CMT + CM. Bacterial pneumonia was diagnosed in five cases (16%) by CMT and in 13 cases (42%) by CMT + CM; fungal pneumonia was diagnosed in six cases (19%) by CMT and in seven cases (23%) by CMT + CM, and viral pneumonia was diagnosed in two cases (6%) by CMT and in five cases (16%) by CMT + CM. The hypothetical impact of CMT + CM on management was deemed probable in one case, possible in eight cases, and unlikely in two cases, whereas the impact on antimicrobial stewardship was possible in 13 cases and unlikely in seven cases. Final clinical diagnoses were made in 20 of 31 cases (65%) based on CMT and in 23 of 31 cases (74%) based on CMT + CM. INTERPRETATION: CMT + CM increased diagnostic yield in immunocompromised adults with pneumonia from 35% to 58%, mostly by the detection of additional bacterial causes but was less useful for fungal pneumonia.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Azar MM, Schlaberg R, Malinis MF, et al. Added Diagnostic Utility of Clinical Metagenomics for the Diagnosis of Pneumonia in Immunocompromised Adults. Chest. 2020. PMID: 33217418. doi:10.1016/j.chest.2020.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。